domvanalimab,pembrolizumab,pemetrexed,cisplatin,gemcitabine,tebentafusp
apexigen,arcus biosciences,merck,otsuka,immunocore,cogent biosciences,gilead
['apex', 'keytruda', 'lung', 'domvana', 'apexigen', 'immunocore', '$imcr', '$mrk', '$apgn', '$gild']
pharma/biotech highlights: $mrk: keytruda + chemotherapy reduce lung cancer.
$imcr: immunocore shares ctdna data at asco.
$cogt: positive combo trial for stomach cancer.
$apgn: apexigen's cd40 antibody shows promise.
$gild: domvanalimab improves non-small cell lung cancer. 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt